Researcher Profile

Researcher Profile

Patrick Chi-Chung Ma, MD, MSc

Patrick Chi-Chung Ma, MD, MSc

Professor, Department of Medicine
Interim Chief, Division of Hematology and Oncology
Scientific Program:Next-Generation Therapies
pcm5221@psu.edu

Research Interests

  • Therapeutics
  • Neoplasms
  • Non-Small Cell Lung Carcinoma
  • Lung Neoplasms
  • Mutation
  • Small Cell Lung Carcinoma
  • ErbB Receptors
  • Hepatocyte Growth Factor
  • Neoplasm Metastasis
  • Protein-Tyrosine Kinases
  • Adenocarcinoma of Lung
  • Erlotinib Hydrochloride

Clinical Trials

APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C mutation (MRT849-001)
A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
Phase II, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
S1827 A randomized Phase III trial comparing prophylactic cranial irradiation (PCI) for any patient with small cell lung cancer (either extensive or limited stage) to active surveillance with MRI in place of PCI
A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) Big Ten Cancer Research Consortium BTCRC-LUN19-396
NRG-LU007 Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial
DuRvalumab MEDI4730 with chEmotherapy as first line treAtment in advanced pleural Mesothelioma A phase 3 Randomised trial (DREAM3R)
Phase Ib Study of Brigatinib Plus Bevacizumab in Patients with ALK- rearranged Non-Small Cell Lung Cancer (NSCLC) Who Have Previously Progressed on Prior ALK-Directed Therapy
A Phase II, Multicenter, Randomized, Open-Label Trial of GEN1046 as monotherapy and in Combination with Anti-cancer Therapy in Subjects with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer who failed first-line Standard of Care therapy with an Immune Checkpoint Inhibitor
Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study
NRG HN009- Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
S1914 A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer

Recent Publications

2022

Kim, SY, Yin, J, Bohlman, S, Walker, P, Dacic, S, Kim, C, Khan, H, Liu, SV, Ma, PC, Nagasaka, M, Reckamp, KL, Abraham, J, Uprety, D, Wang, F, Xiu, J, Zhang, J, Cheng, H & Halmos, B 2022, 'Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing', JTO Clinical and Research Reports, vol. 3, no. 9, 100381. https://doi.org/10.1016/j.jtocrr.2022.100381
Esposito, R, Polidori, T, Meise, DF, Pulido-Quetglas, C, Chouvardas, P, Forster, S, Schaerer, P, Kobel, A, Schlatter, J, Kerkhof, E, Roemmele, M, Rice, ES, Zhu, L, Lanzós, A, Guillen-Ramirez, HA, Basile, G, Carrozzo, I, Vancura, A, Ullrich, S, Andrades, A, Harvey, D, Medina, PP, Ma, PC, Haefliger, S, Wang, X, Martinez, I, Ochsenbein, AF, Riether, C & Johnson, R 2022, 'Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities', Cell Genomics, vol. 2, no. 9, 100171. https://doi.org/10.1016/j.xgen.2022.100171
Shen, C, Holguin, RAP, Schaefer, E, Zhou, S, Belani, CP, Ma, PC & Reed, MF 2022, 'Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma', BMC health services research, vol. 22, no. 1, 470. https://doi.org/10.1186/s12913-022-07857-y

2021

Mattes, MD, Eubank, TD, Almubarak, M, Wen, S, Marano, GD, Jacobson, GM & Ma, PC 2021, 'A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non–Small Cell Lung Cancer', Clinical Lung Cancer, vol. 22, no. 4, pp. 268-273. https://doi.org/10.1016/j.cllc.2021.01.012
Ma, PC 2021, 'ADAURA: The role of adjuvant EGFR TKI and future consideration (Pro)', Precision Cancer Medicine, vol. 4, no. March, 6. https://doi.org/10.21037/pcm-2020-mnsclc-10
Khan, SA, Sun, Z, Dahlberg, S, Malhotra, J, Keresztes, R, Ikpeazu, C, Ma, P, Ramalingam, SS & Pillai, R 2021, 'Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)', JTO Clinical and Research Reports, vol. 2, no. 5, 100166. https://doi.org/10.1016/j.jtocrr.2021.100166
He, Y, Chen, L, Zhao, L, Dang, S, Liu, G, Sasada, S, Ma, PC, Zandwijk, NV, Rosell, R, Popper, HH, Wang, H, Jiang, M, Guo, H, Liu, X, Chen, S, Zhang, X, Xu, M, Zhu, B, Liu, M & Zhou, C 2021, 'Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC', Theranostics, vol. 11, no. 14, pp. 7092-7109. https://doi.org/10.7150/thno.58039
Albandar, HJ, Fuqua, J, Albandar, JM, Safi, S, Merrill, SA & Ma, PC 2021, 'Immune-related adverse events (Irae) in cancer immune checkpoint inhibitors (ici) and survival outcomes correlation: To rechallenge or not?', Cancers, vol. 13, no. 5, 989, pp. 1-15. https://doi.org/10.3390/cancers13050989
Nagasaka, M, Asad, MFB, Al Hallak, MN, Uddin, MH, Sukari, A, Baca, Y, Xiu, J, Magee, D, Mamdani, H, Uprety, D, Kim, C, Xia, B, Liu, SV, Nieva, JJ, Lopes, G, Bepler, G, Borghaei, H, Demeure, MJ, Raez, LE, Ma, PC, Puri, S, Korn, WM & Azmi, AS 2021, 'Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)', Lung Cancer, vol. 160, pp. 92-98. https://doi.org/10.1016/j.lungcan.2021.08.010
Lee, M, Jain, P, Wang, F, Ma, PC, Borczuk, A & Halmos, B 2021, 'MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies', Expert Opinion on Therapeutic Targets, vol. 25, no. 4, pp. 249-268. https://doi.org/10.1080/14728222.2021.1925648

2020

Attia, CG, Fei, N, Almubarak, M, Ma, PC & Mattes, MD 2020, 'Patterns of disease progression to checkpoint inhibitor immunotherapy in patients with stage IV non-small cell lung cancer', Journal of Medical Imaging and Radiation Oncology, vol. 64, no. 6, pp. 866-872. https://doi.org/10.1111/1754-9485.13096
Brownmiller, T, Juric, JA, Ivey, AD, Harvey, BM, Westemeier, ES, Winters, MT, Stevens, AM, Stanley, AN, Hayes, KE, Sprowls, SA, Gatesman Ammer, AS, Walker, M, Bey, EA, Wu, X, Lim, ZF, Zhu, L, Wen, S, Hu, G, Ma, PC & Martinez, I 2020, 'Y chromosome LncRNA are involved in radiation response of male non-small cell lung cancer cells', Cancer Research, vol. 80, no. 19, pp. 4046-4057. https://doi.org/10.1158/0008-5472.CAN-19-4032

2019

Ma, PC 2019, '(Not giving up) the marathon race of Met targeting therapy: Are we there yet?', Clinical Cancer Research, vol. 25, no. 8, pp. 2375-2378. https://doi.org/10.1158/1078-0432.CCR-18-3739
Jonna, S, Feldman, RA, Swensen, J, Gatalica, Z, Korn, WM, Borghaei, H, Ma, PC, Nieva, JJ, Spira, AI, Vanderwalde, AM, Wozniak, AJ, Kim, ES & Liu, SV 2019, 'Detection of NRG1 gene fusions in solid tumors', Clinical Cancer Research, vol. 25, no. 16, pp. 4966-4972. https://doi.org/10.1158/1078-0432.CCR-19-0160
Lim, ZF & Ma, PC 2019, 'Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy', Journal of Hematology and Oncology, vol. 12, no. 1, 134. https://doi.org/10.1186/s13045-019-0818-2
Chen, R, Xia, W, Wang, S, Xu, Y, Ma, Z, Xu, W, Zhang, E, Wang, J, Fang, T, Zhang, Q, Dong, G, Cho, WCS, Ma, PC, Brandi, G, Tavolari, S, Ujhazy, P, Metro, G, Popper, HH, Yin, R, Qiu, M & Xu, L 2019, 'Long Noncoding RNA SBF2-AS1 Is Critical for Tumorigenesis of Early-Stage Lung Adenocarcinoma', Molecular Therapy - Nucleic Acids, vol. 16, pp. 543-553. https://doi.org/10.1016/j.omtn.2019.04.004
Wu, X, Zhu, L & Ma, PC 2019, NTRK-Targeted Therapy in Lung Cancer. in Current Cancer Research. Current Cancer Research, Springer Nature, pp. 137-161. https://doi.org/10.1007/978-3-030-17832-1_7
Ahmad, Z, Stanazai, Q, Wright, S, Smolkin, M & Ma, PC 2019, 'Primary pleural epithelioid sarcoma of the proximal type: A diagnostic and therapeutic challenge', Translational Lung Cancer Research, vol. 8, no. 5, pp. 700-705. https://doi.org/10.21037/tlcr.2019.09.16
Morgensztern, D, Rose, M, Waqar, SN, Morris, J, Ma, PC, Reid, T, Brzezniak, CE, Zeman, KG, Padmanabhan, A, Hirth, JA, I. Spira, A, Trepel, JB & Padda, SK 2019, 'RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer', British Journal of Cancer, vol. 121, no. 3, pp. 211-217. https://doi.org/10.1038/s41416-019-0504-8
Kibirova, A, Mattes, MD, Smolkin, M & Ma, PC 2019, 'The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance', Case Reports in Oncology, vol. 12, no. 3, pp. 765-776. https://doi.org/10.1159/000503417

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)